The U.S. Food and Drug Administration on March 3, 2026, issued 30 warning letters to telehealth companies including Bliv Wellness, Belle Health, FitRX, BluefitMD, Viv Health, 24HrDoc, and GoodGirlRx, alleging that their websites made false or misleading claims about compounded semaglutide and tirzepatide products. The letters, sent February 20 and made public two weeks later, represent the second wave of enforcement since the agency launched a broader crackdown on misleading direct-to-consumer drug advertising in September 2025, as reported by Reuters.
FDA Commissioner Marty Makary, M.D., M.P.H., framed the action in blunt terms. "It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action," Makary said in the agency's press release. He added that compounders "should not try to circumvent FDA's approval process by mass-marketing compounded drugs." The volume of enforcement is striking: Pharmaceutical Commerce reported that the FDA dispatched more warning letters to pharmaceutical and telehealth firms in the preceding six months than over the entire prior decade.
The timing of renewed trade coverage, including Patient Care Online's August 28 summary, places the March enforcement within a wider regulatory arc. In late July, an FDA advisory committee voted to recommend that six previously restricted peptides move toward Category 1 compounding eligibility. That advisory recommendation, which does not constitute a final rule, sits in tension with the agency's simultaneous prosecution of companies marketing compounded GLP-1 receptor agonists as though they were interchangeable with approved brands. The FDA is tightening marketing rules at the top while debating access at the bottom.
Figure 1: The two FDA warning-letter theories—equivalence claims and obscured compounding sourcing—and how they intersect with telehealth GLP-1 business models.
Two violations, one business model
The warning letters identify two primary categories of violation under the Federal Food, Drug, and Cosmetic Act. First, the FDA cited "sameness" claims: promotional materials implying that compounded versions of semaglutide or tirzepatide are identical to, or therapeutically equivalent to, approved products such as Ozempic, Wegovy, Mounjaro, and Zepbound. A smaller number of letters also referenced compounded liraglutide. Second, the agency flagged obscured sourcing. Several telehealth firms branded compounded drugs with their own trademarks or proprietary labels without disclosing that a separate compounding pharmacy manufactured the product, effectively presenting themselves as the compounder.
FDA Deputy Director of Compliance Matt Lash articulated the legal theory in language quoted by The Hill: "Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded." Lash requested that each recipient provide a written response explaining corrective steps, which could include identifying the entities producing their compounded GLP-1 products, submitting sample product labeling, or modifying the cited claims on their platforms.
The misbranding designation carries concrete weight. Compounded drugs, prepared by licensed pharmacists to meet individual patient needs, do not undergo FDA premarket review for safety, efficacy, or quality. For telehealth companies that built subscription models around low-cost compounded semaglutide as an alternative to brand-name prescriptions, the warning letters challenge the foundational marketing premise. The legal shield of "custom compounding" under Sections 503A and 503B of the FD&C Act was designed for patient-specific formulations, not mass-market distribution through digital storefronts. Legal analysis from Gardner Law noted that the FDA is establishing compounding cannot serve as a vehicle to bypass approval requirements for widely advertised obesity and diabetes treatments.
Parallel enforcement and the Hims & Hers referral
The warning letters did not arrive in isolation. On February 6, 2026, Department of Health and Human Services General Counsel Mike Stuart announced that the agency had referred Hims & Hers Health to the Department of Justice for investigation, following FDA concerns about the company's $49 compounded weight-loss pill. That referral, documented in telehealth industry reporting, introduced a criminal-enforcement vector alongside the civil warning-letter track.
The distinction matters for compliance officers. A warning letter is an agency notice requiring a response within 15 business days; it is not a court judgment. But the letters explicitly state that failure to correct violations could result in "legal action without further notice, including, without limitation, seizure and injunction," according to Fierce Pharma's coverage. The DOJ referral against Hims & Hers signals that the agency is willing to escalate beyond administrative remedies when it believes the violations are systemic.
For companies sourcing peptide active pharmaceutical ingredients through cross-border supply chains, particularly from manufacturers in East and South Asia, the obscured-sourcing violation introduces a traceability obligation. A telehealth firm that brands a compounded product under its own name without naming the compounding pharmacy assumes regulatory exposure that extends beyond marketing language into supply-chain documentation. This enforcement posture aligns with broader FDA efforts to tighten oversight of imported drug substances, a development with direct implications for Pacific-region biotech suppliers who provide bulk peptide intermediates to U.S. compounders. The question of whether a compounded product qualifies as a legitimate patient-specific preparation or an unapproved new drug turns partly on whether its ingredient trail is transparent.
What remains unresolved
The 30 March letters are not the final word. On June 8, 2026, the FDA issued a follow-on batch of 25 additional warning letters to telehealth and compounding companies, posted publicly on June 16, citing similar claims of equivalence to approved drugs and use of "FDA-approved" sourcing language in weight-loss marketing. Whether any of the original 30 recipients have corrected their practices, faced seizure actions, or received injunctions has not been made public as of late August.
The July advisory committee vote recommending six peptides for Category 1 compounding eligibility adds a layer of regulatory ambiguity. That recommendation, reported in Sun Sentinel coverage of the peptide market in Florida, does not alter the misbranding analysis applied to GLP-1 marketing. A compounder may gain broader eligibility to prepare certain peptides while still facing prohibition against advertising those preparations as equivalent to approved drugs. The distinction between what may be compounded and how it may be marketed remains the operative line. Whether weight loss peptides fall on one side or the other of that line depends on the specific product and its promotional claims. For firms tracking which compounds hold cleared status, the agency's current list of fda approved peptides and the broader question of are peptides legal under federal law continue to shift as advisory recommendations move through the rulemaking pipeline.
The 15 business-day response window for the March letters expired in late March. No public record indicates how many of the 30 named companies submitted corrective-action plans, and the FDA has not announced follow-up enforcement against any specific recipient. Commissioner Makary's office has not scheduled a press briefing on compliance outcomes. The next concrete step, if the agency follows its stated escalation path, would be a seizure or injunction filing in federal court.
